Promising combo for rare cancer mutation stalls as study ends early
NCT ID NCT06682806
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new drug called PRT3789 combined with the immunotherapy pembrolizumab (Keytruda) in people with advanced solid tumors that have a SMARCA4 gene mutation. The goal was to see if the combination was safe and could shrink tumors. However, the study was terminated early and only enrolled 6 participants, so we have very limited information about how well it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PRT3789 and pembrolizumab (Keytruda)
What this could lead to
If it works, this combination could offer a new treatment option for people with hard-to-treat cancers that have a specific genetic change (SMARCA4 mutation).
What could go wrong
The study was terminated early and only enrolled 6 people, so there is very little data. It is too early to know if the combination is safe or effective, and it may not work at all.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Florida Cancer Specialists
West Palm Beach, Florida, 33401, United States
-
Hospital Universitario Fundacion Jimenez Diaz - Servicio de Oncologia
Madrid, 28040, Spain
-
IOB - Next Oncology - Hospital Quironsalud Barcelona
Barcelona, 08023, Spain
-
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
START Barcelona - HM Nou Delfos
Barcelona, 08023, Spain
-
Tennessee Oncology, PLLC - Greco-Hainsworth Centers for Research
Nashville, Tennessee, 37203, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States